Dr. Eric van der Veer (CSO & founder) joined the Nephrology department of the Leiden University Medical Center (LUMC) as Post-doc fellow in 2007. During his extensive research period (2007-2015) he focused mainly on RNA-based therapies for kidney targets. Due to his many successful publications, he was asked to become Assistant Professor at Leiden University.
In October 2015, he learned about the devastating clinical complications that the kidney virus (BK-virus) can cause. He connected the dots between the characteristics of antisense oligonucleotides (target-specificity & kidney accumulation) & BK-virus and started Hybridize Therapeutics.
In September 2019, Dr. Eric van der Veer decided to create a spin-off and officially found Hybridize Therapeutics. Currently, Hybridize Therapeutics is in the pre-clinical phase for a therapy against BK-virus and in the early pre-clinical phase for a therapy against JC-virus.
Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.